203 related articles for article (PubMed ID: 33655066)
1. Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States.
Lim S; Khoo R; Juang YC; Gopal P; Zhang H; Yeo C; Peh KM; Teo J; Ng S; Henry B; Partridge AW
ACS Cent Sci; 2021 Feb; 7(2):274-291. PubMed ID: 33655066
[TBL] [Abstract][Full Text] [Related]
2. Exploring Targeted Degradation Strategy for Oncogenic KRAS
Zeng M; Xiong Y; Safaee N; Nowak RP; Donovan KA; Yuan CJ; Nabet B; Gero TW; Feru F; Li L; Gondi S; Ombelets LJ; Quan C; Jänne PA; Kostic M; Scott DA; Westover KD; Fischer ES; Gray NS
Cell Chem Biol; 2020 Jan; 27(1):19-31.e6. PubMed ID: 31883964
[TBL] [Abstract][Full Text] [Related]
3.
Miyamoto-Sato E; Imanishi S; Huang L; Itakura S; Iwasaki Y; Ishizaka M
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513471
[TBL] [Abstract][Full Text] [Related]
4. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
[TBL] [Abstract][Full Text] [Related]
5. A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS.
Bery N; Miller A; Rabbitts T
Nat Commun; 2020 Jun; 11(1):3233. PubMed ID: 32591521
[TBL] [Abstract][Full Text] [Related]
6. Targeted Degradation of Oncogenic KRAS
Bond MJ; Chu L; Nalawansha DA; Li K; Crews CM
ACS Cent Sci; 2020 Aug; 6(8):1367-1375. PubMed ID: 32875077
[TBL] [Abstract][Full Text] [Related]
7. Discovery of
Shin Y; Jeong JW; Wurz RP; Achanta P; Arvedson T; Bartberger MD; Campuzano IDG; Fucini R; Hansen SK; Ingersoll J; Iwig JS; Lipford JR; Ma V; Kopecky DJ; McCarter J; San Miguel T; Mohr C; Sabet S; Saiki AY; Sawayama A; Sethofer S; Tegley CM; Volak LP; Yang K; Lanman BA; Erlanson DA; Cee VJ
ACS Med Chem Lett; 2019 Sep; 10(9):1302-1308. PubMed ID: 31531201
[TBL] [Abstract][Full Text] [Related]
8. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.
Chuang HC; Huang PH; Kulp SK; Chen CS
Pharmacol Res; 2017 Mar; 117():370-376. PubMed ID: 28077300
[TBL] [Abstract][Full Text] [Related]
10. Progress on Covalent Inhibition of KRAS(G12C).
Westover KD; Jänne PA; Gray NS
Cancer Discov; 2016 Mar; 6(3):233-4. PubMed ID: 26951837
[TBL] [Abstract][Full Text] [Related]
11. Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes.
Cirstea IC; Gremer L; Dvorsky R; Zhang SC; Piekorz RP; Zenker M; Ahmadian MR
Hum Mol Genet; 2013 Jan; 22(2):262-70. PubMed ID: 23059812
[TBL] [Abstract][Full Text] [Related]
12. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
13. High-throughput, single-particle tracking reveals nested membrane domains that dictate KRas
Lee Y; Phelps C; Huang T; Mostofian B; Wu L; Zhang Y; Tao K; Chang YH; Stork PJ; Gray JW; Zuckerman DM; Nan X
Elife; 2019 Nov; 8():. PubMed ID: 31674905
[TBL] [Abstract][Full Text] [Related]
14. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.
Pan T; Zhang Y; Zhou N; He X; Chen C; Liang L; Duan X; Lin Y; Wu K; Zhang H
Oncotarget; 2016 Jul; 7(28):44299-44309. PubMed ID: 27322423
[TBL] [Abstract][Full Text] [Related]
15. Covalent Guanosine Mimetic Inhibitors of G12C KRAS.
Xiong Y; Lu J; Hunter J; Li L; Scott D; Choi HG; Lim SM; Manandhar A; Gondi S; Sim T; Westover KD; Gray NS
ACS Med Chem Lett; 2017 Jan; 8(1):61-66. PubMed ID: 28105276
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
17. KRAS
Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
[TBL] [Abstract][Full Text] [Related]
18. Drugging K-Ras
Ni D; Li X; He X; Zhang H; Zhang J; Lu S
Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
[TBL] [Abstract][Full Text] [Related]
19. Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules.
Goody RS; Müller MP; Rauh D
Cell Chem Biol; 2019 Oct; 26(10):1338-1348. PubMed ID: 31378709
[TBL] [Abstract][Full Text] [Related]
20. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]